<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/212280-e-2-4-4-chloro-1-2-diphenyl-but-1-enyl-phenoxy-ethanol-and-pharmaceutical-compositions-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:27:30 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 212280:&quot;E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT -1-ENYL)PHENOXY] ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF &quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT -1-ENYL)PHENOXY] ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF &quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to E-2-[4-(4-chloro-1,2-dipheny1-but-1-eny1)phenpxy] ethanol useful in lowering serum cholesterol and to pharmaceutical compositions thereof . A method of lowering of lowering serum cholesterol and a method and a method for the prevention or treatment of anther sclerosis is also disclosed.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT-1 -ENYL)PHENOXY]ETHANOL AND<br>
PHARMACEUTICAL COMPOSITIONS THEREOF<br>
The present invention relates to E-2-[4-(4-chloro-1,2-diphenyl-but-1-<br>
enyl)phenoxy]ethanol (I) having serum cholesterol lowering properties and to<br>
pharmaceutical compositions thereof. Compound (I) is useful in reducing serum<br>
cholesterol levels and in the treatment of atherosclerosis. It is also potentially useful<br>
in the hormone replacement therapy (HRT).<br>
It has been demonstrated that elevated levels of serum cholesterol associated<br>
with low density lipoproteins (LDL) are a major contributing factor in the<br>
development and progression of atherosclerosis. Therefore it is desirable to provide a<br>
method for reducing serum cholesterol levels in patients with hypercholesterolemia<br>
or at risk of developing hypercholesterolemia.<br>
International patent application WO 97/32574 describes the use of<br>
Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol for lowering serum<br>
cholesterol. The compound has no significant estrogenic side effects in uterine tissue<br>
but is able to block the adverse effects of estrogen on uterus. Therefore this<br>
compound is especially useful in lowering serum cholesterol. The corresponding E-<br>
isomer is not described in this patent application.<br>
Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol is a metabolite of<br>
known antiestrogen drug toremifene. Toremifene (Z-4-chloro-1,2-diphenyl-1-[4-[2-<br>
(N,N-dimethylamino)ethoxy]-phenyI]-1-butene) is currently used clinically for the<br>
treatment of estrogen receptor positive breast cancer.<br>
Now it has been found that E-2-[4-(4-chloro-1,2-diphenyl-but-1-<br>
enyl)phenoxy]ethanol (I) is significantly more potent in lowering serum total<br>
cholesterol but approximately equal in uterine effects when compared to the<br>
corresponding Z-isomer. This was unexpected since the E-isomer of toremifene is<br>
purely estrogenic in uterine tissue. Furthermore, it has been found that the E-isomer<br>
of the invention is able to inhibit cholesterol biosynthesis directly whereas the<br>
corresponding Z-isomer has not such effect.<br>
Thus, E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol (I) is<br>
especially useful in lowering serum cholesterol and in the prevention or treatment of<br>
atherosclerosis. Compound (I) is also potentially useful in the hormone replacement<br>
therapy (HRT).<br>
Accordingly, the invention provides a novel compound useful in lowering<br>
serum cholesterol levels said compound being E-2-[4-(4-chloro-1,2-diphenyl-but-1 -<br>
enyl)phenoxy]ethanol and having the structure (I)<br><br>
or a pharmaceutically acceptable ester thereof.<br>
Pharmaceutically acceptable esters include esters made with aliphatic<br>
carboxylic acids, preferably C1-6 acids, e.g. acetic acid, and made with aroma-tic<br>
carboxylic acids, e.g. C7-12 acids such as benzoic acid. The aliphatic and aromatic<br>
acids may optionally be substituted by e.g. one or more C1-4alkyl.<br>
The invention also provides a pharmaceutical composition comprising E-2-<br>
[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol or a pharmaceutically<br>
acceptable ester thereof as an active ingredient together with a pharmaceutically<br>
acceptable carrier.<br>
The invention also provides a method of lowering serum cholesterol levels<br>
which method comprises administering to a patient in need of such treatment an<br>
effective amount of E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol or a<br>
pharmaceutically acceptable ester thereof.<br>
The invention also provides a method for the prevention or treatment of<br>
atherosclerosis which method comprises administering to a patient in need of such<br>
treatment an effective amount of E-2-[4-(4-chloro-1,2-diphenyl-but-1-<br>
enyl)phenoxy]ethanol or a pharmaceutically acceptable ester thereof.<br>
The invention also provides a method of hormone replacement therapy (HRT)<br>
which method comprises administering to a patient in need of such therapy an<br>
effective amount of E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol or a<br>
pharmaceutically acceptable ester thereof.<br>
The compound of the invention may be administered in a variety of ways<br>
including orally, parenterally or transdermally using conventional forms of<br>
preparations, such as capsules, tablets, granules, powders, suppositories, injections,<br>
patches, suspensions and syrups. The term "effective amount" means an amount of<br>
compound of the invention which is capable of lowering serum total cholesterol<br>
levels or capable of blocking the adverse effects of estrogen particularly on uterus or<br>
inhibiting menopausal symptoms. The compound of the invention may be<br>
administered according to the method of the invention monthly, weekly or daily or<br>
several times a day depending upon the patient"s needs. A typical daily oral dosage is<br>
within the range of from about 0.5 mg to about 1000 mg, preferably from about 10<br>
mg to about 800 mg, of the active compound. However, the dosage may be properly<br>
varied depending on the age, body weight and conditions of the patient as well as on<br>
the administration method. The compound of the invention may be administered<br>
alone or together with other active compounds.<br>
The compositions according to the invention can be prepared by the methods<br>
commonly employed in the art. In addition to the active compound the compositions<br>
may contain pharmaceutically acceptable additives commonly used in the art, such as<br>
carriers, binders, excipients, lubricants, suspending agents and diluents. The amount<br>
of the active compound in the compositions of the invention is sufficient to produce<br>
the desired therapeutical effect, for example about 0.5 to 1000 mg, preferably about<br>
10 mg to 800 mg, in unit dosage for both oral and parenteral administration.<br>
The following examples illustrate the synthesis of the compound of the<br>
invention.<br>
EXAMPLES<br>
Example 1. Preparation of E-2-[4-(4-chloro-1,2-diphenyl-but-1-<br>
enyl)phenoxy]ethanol<br>
a) E-4-[4-(2-benzyloxyethoxy)phenyl]-3,4-diphenyl-but-3-en-1 -ol<br>
The alkylation of the starting phenol with benzyl-(2-bromoethyl)ether was<br>
carried out as described in Example 1 of the International Patent Application WO<br>
96/07402 with the exception that now the starting compound was the other geometric<br>
isomer, E-4-(4-hydroxy-l,2-diphenyl-but-1-enyl)-phenol which was prepared by the<br>
method described in United States Patent 4,996,225. The product was extracted to<br>
toluene. The toluene phases were combined, washed with water, dried and<br>
evaporated to dryness. The residue was recrystallized from a minor quantity of<br>
toluene and the precipitated product was used in the next step without further<br>
purification.<br>
1H NMR (300 MHz, CDCl3): 2.8 (2H, t, CH2-C=), 3.6 (2H. dt, CH2OH), 3.8<br>
(2H, t, CH2OBn), 4.2 (2H, t, CH2OPh), 4.6 (2H, s, OCH2Ph), 6.8 - 7.4 (19H, m).<br>
b) E-1 -[4-(2-benzyloxyethoxy)phenyI]-4-chloro-1,2-diphenyl-but-1 -ene<br>
The halogenation of E-4-[4-(2-benzyloxyethoxy)phenyl]-3,4-diphenyl-but-3-<br>
en-1-ol was carried out as described in Example 2 of the International Patent<br>
Application WO 96/07402 but using E-4-[4-(2-benzyloxyethoxy)-phenyl]-3,4-<br>
dipheny]-but-3-en-1-ol as the starting compound.<br>
1H NMR (300 MHz, CDCl3): 3.0 (2H, t), 3.4 (2H, t), 3.8 (2H, t), 4.2 (2H, t),<br>
4.6(2H, s), 6.9 - 7.4(19H,m).<br>
c) E-2-[4-(4-chloro-1,2-diphenyl-but-1 -enyl)phenoxy]ethanol<br>
6.9 g of E-1 -[4-(2-benzyloxyethoxy)phenyl]-4-chloro-1,2-diphenyl-but-1 -ene<br>
was dissolved in the mixture of ethyl acetate (60 ml) and ethanol (60 ml). Palladium<br>
on carbon (5 %, 0.7 g) was added and the solution was stirred vigorously under a<br>
hydrogen atmosphere at room temperature until there was not any starting compound<br>
left (thin layer chromatography). Palladium on carbon was filtered off through<br>
siliceous earth and the filtrate was evaporated to dryness. The residue was<br>
crystallized several times from the mixture of ethanol and water.<br>
1H NMR (300 MHz, CDCl3): 3.0 (2H, t). 3.4 (2R, t), 4.0 (2H, m), 4.1 (2H.<br>
t),6.8-7.3(14H,m).<br>
MS-spectrum (+EI, 70 eV, direct inlet): 378 (100%), 342 (8%), 329 (43%),<br>
285 (23%), 284 (28%), 207 (32%), 191 (30%).<br>
EXPERIMENTS<br>
Methods<br>
The estrogenic/antiestrogenic activity of the study drug was tested by<br>
measuring the effect on the uterine weight in immature (18 days old) female<br>
Sprague-Dawley rats. The compound was given p.o. in a PEG-solution for 3 days (n<br>
= 5/group). At the same time the ability of the study drug to inhibit estrogen-induced<br>
increase in uterine weight was studied in rats given estradiol 50 µg/kg s.c.<br>
Comparison was made with the corresponding Z-isomer.<br>
The effects on cholesterol biosynthesis was studied in vitro in Hep G2 cell<br>
cultures using I4C-acetate as cholesterol precursor. The test compound was added<br>
into the culture medium at concentrations from 0.01 to 10 micromolar. After 2 hours<br>
the culture was stopped and the newly synthesized cholesterol was quantitated by<br>
thin-layer chromatography. Comparison was made with the Z-isomer.<br>
The effects on uterine weight and on serum cholesterol levels were studied in<br>
intact and ovarectomized adult female Sprague-Dawley rats. In the intact rats the<br>
study drug was given p.o. at a daily dose of 3.17 mg/kg for two weeks and<br>
comparison was made with the equimolar doses of the Z-isomer, toremifene E-<br>
isomer, raloxifene or estradiol. In the ovarectomy study the study drug was given p.o.<br>
at a daily dose of 0.1, 1 or 10 mg/kg for 4 weeks and comparison was made with the<br>
corresponding Z-isomer and estradiol (100 µg/kg). The serum cholesterol content<br>
was determined by an enzymatic method. In the ovarectomy study the serum<br>
cholesterol and cholesterol precursor molecule content was determined by gas-liquid<br>
chromatography.<br>
Results<br>
In the immature rat uterine weight test the E-isomer of the invention showed<br>
approximately equal estrogenic and antiestrogenic effect when compared to the<br>
corresponding Z-isomer. The results are shown in Table 1 wherein 1271b (E) means<br>
the E-isomer of the invention, 1271a (Z) means the corresponding Z-isomer and E2<br>
means estradiol.<br><br>
In the in vitro cell culture system used the E-isomer of the invention inhibited<br>
slightly cholesterol biosynthesis but the Z-isomer had an opposite effect as shown in<br>
Table 2.<br><br>
In adult female rats 1271b (E), 1271a (Z) and raloxifene decreased relative<br>
uterine weight at about the same extent. Instead, estradiol and toremifene E-isomer<br>
increased the weight. Of the drugs 1271b (E), toremifene E-isomer, raloxifene and<br>
estradiol decreased serum cholesterol level with an approximately equal efficacy (by<br>
50-60%). The 1271a (Z) molecule was less effective. The results are shown in Table<br>
3.<br>
TABLE 3.<br>
Drug molecule Relative uterine weight and serum cholesterol content<br>
(control level has been taken as 1.00; mean±SD, n=3)<br>
Uterus Cholesterol<br>
1271b (E) 0.85±0.07 0.43±0.05<br>
1271a (Z) 0.75±0.06 0.65±0.10<br>
Toremifene (E) 1.09±0.10 0.40±0.18<br>
Raloxifene 0.77±0.21 0.48±0.09<br>
Estradiol l.29±0.06 0.48+0.09<br>
In the ovarectomy study 1271b (E) increased slightly (1.5-fold) the relative<br>
uterus weight, not more than the corresponding Z-isomer. Estradiol increased the<br>
weight 3.3-fold. The 1271b (E) decreased serum cholesterol level very efficiently (by<br>
up to 77%), 1271a (Z) was clearly less effective (decrease was up to 34%). The<br>
results are shown in Table 4.<br>
TABLE 3.<br>
Drug molecule Relative uterine weight and serum cholesterol content<br>
(control level has been taken as 1.00; mean±SD, n=3)<br>
Uterus Cholesterol<br>
1271b(E) 0.85±0.07 0.43±0.05<br>
1271a(Z) 0.75±0.06 0.65±0.10<br>
Toremifene (E) 1.09±0.10 0.40±0.18<br>
Raloxifene 0.77±0.21 0.48±0.09<br>
Estradiol l.29±0.06 0.48±0.09<br><br>
Further, in the ovarectomy study it was noticed that 1271b (E) but not 1271a<br>
(Z) increased slightly serum cholesterol precursor molecule level suggesting a direct<br>
cholesterol biosynthesis inhibition by 1271b (E).<br>
Discussion<br>
The above data indicate that both 1271a (Z) and 1271b (E) are equivalent in<br>
antiestrogenicity in rat uterus. This differs from toremifene as toremifene"s E-isomer<br>
is clearly estrogenic in rat uterus and the Z-isomer is antiestrogenic. 1271b (E) is<br>
more efficient as a hypolipidemic agent than the corresponding Z-isomer. This is at<br>
least partly explained by the ability of 1271b (E) to inhibit cholesterol biosynthesis<br>
directly. In summary, the test compound 1271b (E) is an antiestrogenic drug that has<br>
also beneficial and potent hypolipidemic properties.<br>
WE CLAIM :<br>
1. E - 2 - [4 - (4 -chloro-1, 2 - diphenyl - but - 1 - enyl) phenoxy] ethanol or a<br>
pharmaceutically acceptable ester thereof.<br>
2. A pharmaceutical composition which comprises E-2-[4-(4-chloro-l,2-<br>
diphenyl-but-1-enyl)phenoxy]ethanol or a pharmaceutically acceptable ester thereof<br>
as an active ingredient together with a pharmaceutically acceptable carrier.<br>
3. A pharmaceutical composition as claimed in claim 2, for lowering serum<br>
cholesterol.<br>
4. A pharmaceutical composition as claimed in claim 2, for the prevention or<br>
treatment of atherosclerosis.<br>
5. A pharmaceutical composition as claimed in claim 2, for hormone<br>
replacement therapy (HRT).<br>
The present invention relates to E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol useful in lowering serum cholesterol<br>
and to pharmaceutical compositions thereof. A method of lowering serum cholesterol and a method for the prevention or treatment of<br>
atherosclerosis is also disclosed.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtYXNzaWdubWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtY2xhaW1zLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtZ3BhLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtbGV0dGVyIHBhdGVudC5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-letter patent.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtcmVwbHkgdG8gZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtc3BlY2lmaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDAtMDAyMzUta29sLWdyYW50ZWQtdHJhbnNsYXRlZCBjb3B5IG9mIHByaW9yaXR5IGRvY3VtZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2000-00235-kol-granted-translated copy of priority document.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="212279-a-quinolinyl-pyrrolopyrazole-compound-and-pharmaceutical-composition-thereof.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="212281-internal-combustion-engine.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>212280</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>IN/PCT/2000/00235/KOL</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>48/2007</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>30-Nov-2007</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>28-Nov-2007</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>21-Aug-2000</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ORION CORPORATION</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>ORIONINTIE 1, FIN-02200 ESPOO</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SODERVALL MARJA-LIISA</td>
											<td>ANNANTIE 9-13 C7 FIN-90560 OULU</td>
										</tr>
										<tr>
											<td>2</td>
											<td>KALAPUDAS ARJA,</td>
											<td>NOTHOLANTIE 13,FIN –90240 OULU,FINLAND.</td>
										</tr>
										<tr>
											<td>3</td>
											<td>VIITANEN ANTTI,</td>
											<td>KANTOKASKI 6,FIN-02340 ESPOO,FINLAND.</td>
										</tr>
										<tr>
											<td>4</td>
											<td>MANTYLA EERO,</td>
											<td>KAISTISENTIE 41 B, FIN –20760,PIISPANRISTI,FINLAND,</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 43/23</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/FI99/00137</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>1999-02-19</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>9803521.5</td>
									<td>1998-02-19</td>
								    <td>U.K.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/212280-e-2-4-4-chloro-1-2-diphenyl-but-1-enyl-phenoxy-ethanol-and-pharmaceutical-compositions-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:27:31 GMT -->
</html>
